(EVFM) – Company Press Releases
-
Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO
-
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
-
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
-
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
-
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
-
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive
-
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
-
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
-
Evofem to Participate in the Virtual Investor Ask the CEO Conference
-
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi® Until Evofem's Phexxi Patents Expire
-
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
-
Evofem Biosciences Signs Non-Binding Letter of Intent to Enable Listing on a National Stock Exchange
-
Evofem Biosciences Announces Financial Results for the Second Quarter of 2023
-
Evofem to Participate in the Virtual Investor Summer Spotlight Series
-
Evofem Biosciences Announces Financial Results for the First Quarter of 2023
-
Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023
-
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
-
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update
-
Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary
-
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required
-
Evofem Biosciences Announces Cost Reduction Measures
-
Evofem Biosciences Appoints Interim Chief Financial Officer
-
Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering
-
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi
-
Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value
-
Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)
-
Costco Adds Phexxi® to Member Prescription Program
-
Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women
-
Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women
-
OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022
-
Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women
-
Evofem Biosciences Announces Approval of Phexxi in Nigeria
-
Evofem Biosciences Announces Uplisting to OTCQB
-
Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter
-
Inventor of the Year Awarded to Developer of Phexxi®
-
Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide
-
Evofem Announces Successful Debt Restructuring
-
Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022
-
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance
-
Evofem Biosciences Strengthens Board of Directors
-
Evofem Biosciences Discusses Innovative Woman-Controlled Contraceptive with The Stock Day Podcast
-
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women
-
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals
-
Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022
-
Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition
-
Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling
-
Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act
-
Evofem Partners with a360 Media to Support Phexxi® Prescription Growth
-
Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health
Back to EVFM Stock Lookup
